The Joint Corp. (NASDAQ: JYNT) reported Q2 EPS of $0.05, $0.02 better than the analyst estimate of $0.03. Revenue for the quarter came in at $15.2 million versus the consensus estimate of $14.57 million.

2026 Guidance

The Company reiterated its 2026 financial guidance as originally provided on March 12, 2026, as follows:

System-wide comp sales for clinics open 13 months or more are expected to be in the range of (3)% to 3%.

Consolidated Adjusted EBITDA is expected to be in the range of $12.5 million to $13.5 million.

For earnings history and earnings-related data on The Joint Corp. (JYNT) click here.